---
layout: default
title: Panitumumab
parent: 僅模型預測 (L5)
nav_order: 531
evidence_level: L5
indication_count: 2
---

# Panitumumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Panitumumab: From Metastatic Colorectal Cancer (RAS Wild-Type) to Drug-Induced Osteoporosis

## One-Sentence Summary

Panitumumab is a fully human anti-EGFR IgG2 monoclonal antibody, originally indicated for RAS wild-type metastatic colorectal cancer. The TxGNN model predicts a possible link to **drug-induced osteoporosis** (score 99.13%), but this prediction is currently backed by **0 clinical trials** and **0 publications** — it is a model-only signal with no established mechanistic rationale connecting EGFR-pathway inhibition to bone metabolism.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Metastatic Colorectal Cancer (RAS wild-type)* |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

\* Malaysia's official approved-indication text is not present in the current data set (license record fields are empty); this value is drawn from the drug's known global indication as referenced in the evidence pack's own rationale text, not from a Malaysia-specific label.

## Why is This Prediction Reasonable?

Panitumumab is a fully human anti-EGFR IgG2 monoclonal antibody that blocks epidermal growth factor receptor signaling, its established mechanism in RAS wild-type metastatic colorectal cancer.

For the top-ranked prediction, drug-induced osteoporosis, there is **no known or published mechanistic link** between EGFR-pathway blockade and osteoclast/osteoblast regulation. "Drug-induced osteoporosis" is also a descriptive/adverse-effect category rather than a distinct disease entity, which further limits how meaningfully it can be mapped onto a specific drug mechanism. This candidate reflects TxGNN embedding similarity alone, with no supporting biological hypothesis identified.

A second, lower-priority candidate in this evidence pack — severe nonproliferative diabetic retinopathy (score 99.05%) — has a marginally more plausible rationale via EGFR/VEGF crosstalk in angiogenesis research, but likewise has zero clinical or preclinical data specific to panitumumab in this indication, and differs from panitumumab's systemic route versus the local (intravitreal) route typically used for retinal anti-angiogenic therapy.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Cytotoxicity

Panitumumab is an antineoplastic agent (approved for RAS wild-type metastatic colorectal cancer; anti-EGFR monoclonal antibody class).

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is zero clinical, preclinical, or literature evidence for either candidate indication, and the top-ranked candidate (drug-induced osteoporosis) has no identifiable mechanistic connection to panitumumab's known pharmacology — this is an L5, model-prediction-only signal. In addition, TFDA/NPRA label safety data (warnings, contraindications) is a **Blocking** data gap (DG001), which by itself prevents progression to initial safety screening (S1) regardless of indication-level evidence.

**To proceed, the following is needed:**
- TFDA/NPRA product label (warnings, contraindications) to clear the Blocking data gap (DG001)
- Confirmed detailed mechanism of action data (DG001/DG002) to properly evaluate biological plausibility
- Malaysia license record details (product name, dosage form, approved indication text) — current record is empty
- Preclinical or mechanistic studies specifically linking anti-EGFR therapy to bone metabolism before further evaluating the osteoporosis candidate
- If pursuing the secondary candidate (diabetic retinopathy), preclinical data on EGFR-pathway involvement in retinal vasculature specific to panitumumab
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

